C
CDXS
Codexis Inc
1.300
+0.020+1.56%After Hours: 1.310 +0.010 +0.77%16:31 10/26 EDT
OPEN/PREV CLOSE1.300/1.280
TODAY RANGE1.280-1.300
VOL392.38K
MARKET CAP142.36M
52 WEEK RANGE0.9583-2.980
AVG VOL (3M)987.60K
% TURNOVER0.29%
TURNOVER--
P/E (TTM)-3.8371
% RANGE1.56%
EPS(TTM)-0.3388
P/E(FORWARD)-3.4211
P/B3.605
BVPS0.3606
DIVIDEND--
P/S1.671
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP132.24M
SHARES OUTSTANDING109.51M
NEXT EARNINGS11/04-11/09
FREE FLOAT101.73M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·5d ago
Piper Sandler Sticks to Their Buy Rating for Codexis (CDXS)
Seeking Alpha·09/28 11:02
Codexis partners with siRNA drug innovator for enzymatic oligonucleotide synthesis
Dow Jones·09/28 11:00
Codexis Shares Gain on Agreement With Undisclosed Drug Innovator
TipRanks·09/28 10:20
Codexis announces agreement with siRNA drug innovator
TipRanks·09/22 12:56
Codexis (CDXS) Has a New Rating from Stephens
TipRanks·08/20 00:27
Codexis Earnings Call: Margin Gains, Scale-Up Bets
Dow Jones·08/17 16:15
Codexis Price Target Cut to $8.00/Share From $9.00 by Piper Sandler
Dow Jones·08/17 16:15
Codexis Is Maintained at Overweight by Piper Sandler
Benzinga·08/17 16:05
Piper Sandler Maintains Overweight on Codexis, Lowers Price Target to $8
NASDAQ·08/14 16:00
Codexis (CDXS) Upgraded to Buy: What Does It Mean for the Stock?
Simply Wall St·08/12 22:45
Codexis (CDXS) Stock Rallies On Longer Cash Runway Questions Remain
TipRanks·08/12 14:35
Cantor Fitzgerald Keeps Their Buy Rating on Codexis (CDXS)
Same Industry
Name/Symbol
Change%
Price